Researchers from Fairfax, Va.-based George Mason University, Minneapolis-based University of Minnesota and the Memorial Sloan Kettering Cancer Center in New York City analyzed Medicare encounter and claims data from Jan. 1, 2015, to Dec. 31, 2019. The cohort was composed of 96,501 Medicare Advantage and 206,274 traditional Medicare beneficiaries who underwent chemotherapy during that time.
Resource use included inpatient services, outpatient care, Part D drugs and hospice services, according to the study.
The study also compared care quality and overall survival between the two groups. While differences in care quality were mixed, there was no difference found in overall survival.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
